ZFTA–RELA Dictates Oncogenic Transcriptional Programs to Drive Aggressive Supratentorial EpendymomaAmir Arabzade, Stephen C. Mack, Madeline Ngo et al.|Cancer Discovery|2021Cited by 90
Efficacy and Safety of the Bruton's Tyrosine Kinase (BTK) Degrader NX-5948 in Patients with Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL): Updated Results from an Ongoing Phase 1a/b StudyNirav N. Shah, Talha Munir, Zulfa Omer et al.|Blood|2024Cited by 27
Latest Results From an Ongoing First-in-Human Phase 1a/B Study of NX-5948, a Selective Bruton's Tyrosine Kinase (BTK) Degrader, in Patients With Relapsed/Refractory CLL and Other B-Cell MalignanciesKim Linton, Alexey V. Danilov, Graham P. Collins et al.|Clinical Lymphoma Myeloma & Leukemia|2024Cited by 5
Bexobrutideg (NX-5948), a novel Bruton's tyrosine kinase (BTK) degrader, demonstrates rapid and durable clinical responses in Relapsed/Refractory chronic lymphocytic leukemia (CLL): New and updated findings from an ongoing Phase 1a/b trialZulfa Omer, Wojciech Jurczak, Alexey V. Danilov et al.|Blood|2025Cited by 3
CLL-638 Latest Results From an Ongoing Firstin-Human Phase 1a/B Study of NX-5948, a Selective Bruton's Tyrosine Kinase (BTK) Degrader, in Patients With Relapsed/Refractory CLL and Other B-Cell MalignanciesKim Linton, Alexey V. Danilov, Graham P. Collins et al.|Clinical Lymphoma Myeloma & Leukemia|2024Cited by 2